Candriam Luxembourg S.C.A. Trims Position in Enanta Pharmaceuticals Inc (ENTA)

Candriam Luxembourg S.C.A. trimmed its holdings in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 69.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 68,000 shares of the biotechnology company’s stock after selling 157,000 shares during the period. Candriam Luxembourg S.C.A. owned about 0.36% of Enanta Pharmaceuticals worth $3,990,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. First Manhattan Co. boosted its holdings in Enanta Pharmaceuticals by 14.5% during the fourth quarter. First Manhattan Co. now owns 1,084,200 shares of the biotechnology company’s stock worth $63,620,000 after buying an additional 137,100 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Enanta Pharmaceuticals by 6.9% during the second quarter. Vanguard Group Inc. now owns 847,021 shares of the biotechnology company’s stock worth $30,475,000 after buying an additional 54,856 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Enanta Pharmaceuticals by 1.4% during the third quarter. Dimensional Fund Advisors LP now owns 562,394 shares of the biotechnology company’s stock worth $26,320,000 after buying an additional 7,617 shares in the last quarter. Northern Trust Corp boosted its holdings in Enanta Pharmaceuticals by 4.1% during the second quarter. Northern Trust Corp now owns 195,712 shares of the biotechnology company’s stock worth $7,041,000 after buying an additional 7,772 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in Enanta Pharmaceuticals by 23.5% during the third quarter. Ameriprise Financial Inc. now owns 143,817 shares of the biotechnology company’s stock worth $6,730,000 after buying an additional 27,342 shares in the last quarter. Hedge funds and other institutional investors own 68.04% of the company’s stock.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) opened at $81.58 on Friday. Enanta Pharmaceuticals Inc has a 52 week low of $27.24 and a 52 week high of $95.91. The company has a market cap of $1,558.53, a P/E ratio of 42.37 and a beta of 1.04.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing analysts’ consensus estimates of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 13.33% and a net margin of 26.35%. The firm had revenue of $75.93 million during the quarter, compared to analyst estimates of $73.80 million. During the same period in the prior year, the business posted ($0.09) EPS. The company’s revenue for the quarter was up 491.3% on a year-over-year basis. equities research analysts predict that Enanta Pharmaceuticals Inc will post 0.86 earnings per share for the current year.

ENTA has been the subject of a number of research reports. TheStreet upgraded shares of Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Wednesday, December 13th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $54.00 price objective on shares of Enanta Pharmaceuticals in a research note on Friday, October 20th. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $82.00 price objective for the company in a research note on Monday, February 12th. BidaskClub lowered shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 10th. Finally, JPMorgan Chase & Co. lowered shares of Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Thursday, February 8th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $57.40.

COPYRIGHT VIOLATION NOTICE: “Candriam Luxembourg S.C.A. Trims Position in Enanta Pharmaceuticals Inc (ENTA)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/17/candriam-luxembourg-s-c-a-trims-position-in-enanta-pharmaceuticals-inc-enta.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply